Sofosbuvir is a nucleotide analog and direct-acting antiviral agent approved for the treatment of chronic hepatitis C infection. It functions as a prodrug, undergoing intracellular metabolism to form its… Read more













































Sofosbuvir is a nucleotide analog and direct-acting antiviral agent approved for the treatment of chronic hepatitis C infection. It functions as a prodrug, undergoing intracellular metabolism to form its active triphosphate metabolite, which inhibits the NS5B RNA-dependent RNA polymerase to terminate viral replication. Laboratories working with this pharmaceutical agent rely on a comprehensive range of Sofosbuvir reference standards, including pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope labelled compounds. These materials are essential for rigorous quality control, enabling accurate impurity profiling and the development or validation of stability-indicating analytical methods, such as RP-HPLC and LC-MS/MS. Furthermore, these related compounds support forced degradation studies and bioanalytical quantification, ensuring that pharmaceutical development meets stringent regulatory standards. The availability of high-quality, characterized standards facilitates precise monitoring of drug substance consistency and purity throughout the pharmaceutical lifecycle.